Compare Heron Therapeutics Inc (HRTX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is far larger — about 21.3× Heron Therapeutics Inc's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| HRTX | QQQE | |
|---|---|---|
Market Cap | $68.01M | $1.45B |
Volume | 1,891,941 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $124.69 |
52-Week Low | $0.27 | $96.06 |
Typical Hold Time | 35 Days | 48 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
